The National Institutes of Health has been trying to crack down on conflicts of interest, to the point that some NIH researchers declined to give talks to industry, says blogger Derek Lowe at In the Pipeline. At the same time, Lowe points out, NIH is moving toward more translational science, which will mean more interactions with industry. "So how will the NIH manage that if the drug industry is seen as contaminating their Purity of Essence?" he asks.
Most Likely It'll Mean More Forms
Jun 23, 2011